Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care
Open Access
- 30 March 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 102 (8), 1207-1212
- https://doi.org/10.1038/sj.bjc.6605623
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave RoussyAnnals Of Oncology, 2007
- Dynamic evolution of the innate immune system in DrosophilaNature Genetics, 2007
- Comparative genomic analysis of three Leishmania species that cause diverse human diseaseNature Genetics, 2007
- Phylogenomic analysis of natural selection pressure in Streptococcus genomesBMC Evolutionary Biology, 2007
- Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapyThe Breast, 2005
- Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effectsAnnals Of Oncology, 2005
- The Genome of the Kinetoplastid Parasite, Leishmania majorScience, 2005
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993